The call for expressions of interest for Experimental Cancer Medicine Centres (ECMC) is now open.
The ECMC are pleased to announce the official launch of the Quinquennial Review for the period of 2017-2022.
The Expression of Interest (EoI) call is now open to accepting applications for ECMC status for the upcoming quinquennium.
For the first time, Cancer Research UK Centres and the ECMC Network are aligning their review application process in a bid to present a unified vision for cancer research at any given location.
What is expected from an ECMC?
The ECMC award provides infrastructure support over a period of five years to enhance the existing bench-to-bedside pathway by supporting key infrastructure tailored to the needs of each ECMC site.
Over the next five years, the Centres that receive ECMC funding are expected to drive the design and delivery of translational studies and scientifically-driven and rationally designed early-phase oncology trials to the highest international quality, to time and target.
The ECMCs will be encouraged to improve the success rate in developing new therapeutic modalities for patient benefit, by increasing trial capacity, safety and speed.
As the ECMC Network centres on the nature of collaboration, each ECMC should strive to work effectively across other Centres, Universities and Trusts. By increasing the attractiveness of the UK as the industry’s destination of choice, the UK can remain at the forefront of international efforts to develop and test new treatments for cancer, built upon outstanding science and optimal trial design.
All existing ECMCs will undergo a quinquennial review in October 2016 to determine future ECMC status and allocation of funding beyond March 2017.
More information can be found here: http://www.ecmcnetwork.org.uk/news/announcement/launch-ecmc-quinquennial-review
Health and Care Research Wales co-fund Experimental Cancer Medicine Centres with Cancer Research UK and the other Departments of Health from the UK.